Sarvnaz Sadrameli
PharmD
Rotations
Cellular Therapy, Multiple Myeloma, Lymphoma, Supportive Care/Medical Oncology
Education
PharmD: University of Texas at Austin
Residency Training
PGY1: University of Illinois at Chicago
PGY2 Oncology: University of Wisconsin Hospitals and Clinics (UW Health - Madison)
Practice Interests
Cellular therapy, graft-versus-host disease
Professional Affiliation
Hematology/Oncology Pharmacy Association (HOPA)
American Society of Health-System Pharmacists (ASHP)
American Society for Transplantation and Cellular Therapy (ASTCT)
Recent Publications
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM. Authors; Reply to Bonnet et al.; Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”. Drugs. 2021;81(5):615-7.
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-56.
Academic and/or National Presentations
Current Research
Tyrosine kinase inhibitors tolerability assessment in patients with advanced solid tumor malignancies and hypoalbuminemia